CN100531738C - (11β,17β)-11-(1,3-苯并间二氧杂环戊烯-5-基)-17-羟基-17-(1-丙炔基)雌-4,9-二烯-3-酮在治疗重性抑郁症中的应用 - Google Patents

(11β,17β)-11-(1,3-苯并间二氧杂环戊烯-5-基)-17-羟基-17-(1-丙炔基)雌-4,9-二烯-3-酮在治疗重性抑郁症中的应用 Download PDF

Info

Publication number
CN100531738C
CN100531738C CNB028210417A CN02821041A CN100531738C CN 100531738 C CN100531738 C CN 100531738C CN B028210417 A CNB028210417 A CN B028210417A CN 02821041 A CN02821041 A CN 02821041A CN 100531738 C CN100531738 C CN 100531738C
Authority
CN
China
Prior art keywords
treatment
org
patients
propynyl
dien
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028210417A
Other languages
English (en)
Chinese (zh)
Other versions
CN1582153A (zh
Inventor
C·森内夫
B·W·M·M·佩特斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pop Beta Cortisol LLC
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Organon NV filed Critical Organon NV
Publication of CN1582153A publication Critical patent/CN1582153A/zh
Application granted granted Critical
Publication of CN100531738C publication Critical patent/CN100531738C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB028210417A 2001-10-26 2002-10-21 (11β,17β)-11-(1,3-苯并间二氧杂环戊烯-5-基)-17-羟基-17-(1-丙炔基)雌-4,9-二烯-3-酮在治疗重性抑郁症中的应用 Expired - Fee Related CN100531738C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01204072.1 2001-10-26
EP01204072 2001-10-26

Publications (2)

Publication Number Publication Date
CN1582153A CN1582153A (zh) 2005-02-16
CN100531738C true CN100531738C (zh) 2009-08-26

Family

ID=8181136

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028210417A Expired - Fee Related CN100531738C (zh) 2001-10-26 2002-10-21 (11β,17β)-11-(1,3-苯并间二氧杂环戊烯-5-基)-17-羟基-17-(1-丙炔基)雌-4,9-二烯-3-酮在治疗重性抑郁症中的应用

Country Status (26)

Country Link
US (1) US20040266863A1 (enExample)
EP (2) EP1441739B1 (enExample)
JP (1) JP4647909B2 (enExample)
KR (1) KR20050038580A (enExample)
CN (1) CN100531738C (enExample)
AT (2) ATE317700T1 (enExample)
AU (1) AU2002348996B2 (enExample)
BR (1) BR0213466A (enExample)
CA (1) CA2463446C (enExample)
CY (1) CY1110173T1 (enExample)
DE (2) DE60209248D1 (enExample)
DK (1) DK1652526T3 (enExample)
EC (1) ECSP045080A (enExample)
ES (1) ES2319563T3 (enExample)
HR (1) HRP20040370B1 (enExample)
HU (1) HUP0500070A3 (enExample)
IL (2) IL161248A0 (enExample)
IS (1) IS2702B (enExample)
MX (1) MXPA04003781A (enExample)
NO (1) NO332978B1 (enExample)
NZ (1) NZ532429A (enExample)
PL (1) PL206687B1 (enExample)
PT (1) PT1652526E (enExample)
RU (1) RU2302245C2 (enExample)
WO (1) WO2003037354A1 (enExample)
ZA (1) ZA200403088B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050080061A1 (en) * 2003-07-23 2005-04-14 Corcept Therapeutics, Inc. Antiglucocorticoid therapy for the prevention of neurological damage in premature infants
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
EP2292269A3 (en) * 2004-11-19 2011-08-10 N.V. Organon Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
CA2649894A1 (en) * 2006-05-02 2007-11-15 Corcept Therapeutics, Inc. The use of a glucocorticoid receptor ii antagonist to treat depression in patients taking il-2
WO2012106514A2 (en) * 2011-02-03 2012-08-09 Pop Test Cortisol Llc System and method for diagnosis and treatment
EP2699245A4 (en) * 2011-04-18 2014-12-10 Pop Test Cortisol Llc TREATMENT AGAINST HAIR LOSS
US8986677B2 (en) * 2012-07-30 2015-03-24 Pop Test Cortisol Llc Therapeutic compositions and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
CN1147520A (zh) * 1995-08-17 1997-04-16 阿克佐诺贝尔公司 11-(取代的苯基)-雌-4，9-二烯衍生物
CN1272788A (zh) * 1997-10-06 2000-11-08 利兰·斯坦福青年大学托管委员会 治疗糖皮质素功能失调相关性精神病的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4447401A1 (de) * 1994-12-23 1996-07-04 Schering Ag 14,17-C¶2¶-überbrückte Steroide
DE19727772A1 (de) * 1997-06-30 1999-01-28 Forschungszentrum Juelich Gmbh Magnetflußsensor mit ringförmiger Sonde
CN1556709A (zh) * 2001-03-23 2004-12-22 �Ƹ��� 使用糖皮质激素受体特效拮抗剂治疗压力症的方法
IL158744A0 (en) * 2001-05-04 2004-05-12 Corcept Therapeutics Inc Methods for treating delirium using glucocorticoid receptor-specific antagonists
MXPA04001893A (es) * 2001-08-31 2005-03-07 Corcept Therapeutics Inc Metodos para inhibir deterioro cognoscitivo en adultos con sindrome de down.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4814333A (en) * 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
CN1147520A (zh) * 1995-08-17 1997-04-16 阿克佐诺贝尔公司 11-(取代的苯基)-雌-4，9-二烯衍生物
CN1272788A (zh) * 1997-10-06 2000-11-08 利兰·斯坦福青年大学托管委员会 治疗糖皮质素功能失调相关性精神病的方法

Also Published As

Publication number Publication date
IL161248A0 (en) 2004-09-27
PL206687B1 (pl) 2010-09-30
PL369261A1 (en) 2005-04-18
HUP0500070A3 (en) 2012-09-28
IL161248A (en) 2010-12-30
WO2003037354A1 (en) 2003-05-08
RU2004116082A (ru) 2005-05-10
CA2463446A1 (en) 2003-05-08
EP1441739A1 (en) 2004-08-04
JP2005521637A (ja) 2005-07-21
EP1652526B1 (en) 2009-01-14
EP1652526A3 (en) 2006-08-02
HRP20040370B1 (hr) 2012-09-30
ATE317700T1 (de) 2006-03-15
PT1652526E (pt) 2009-02-06
DE60209248D1 (de) 2006-04-20
EP1652526A2 (en) 2006-05-03
CA2463446C (en) 2010-02-23
IS7204A (is) 2004-03-31
NZ532429A (en) 2004-10-29
HRP20040370A2 (en) 2004-08-31
ZA200403088B (en) 2005-01-24
HUP0500070A2 (hu) 2005-04-28
NO20041651L (no) 2004-04-23
RU2302245C2 (ru) 2007-07-10
ECSP045080A (es) 2004-06-28
ES2319563T3 (es) 2009-05-08
MXPA04003781A (es) 2004-07-30
JP4647909B2 (ja) 2011-03-09
DK1652526T3 (da) 2009-05-18
US20040266863A1 (en) 2004-12-30
NO332978B1 (no) 2013-02-11
KR20050038580A (ko) 2005-04-27
IS2702B (is) 2010-11-15
BR0213466A (pt) 2004-11-09
CY1110173T1 (el) 2015-01-14
DE60230936D1 (de) 2009-03-05
AU2002348996B2 (en) 2008-06-05
CN1582153A (zh) 2005-02-16
HK1087357A1 (en) 2006-10-13
EP1441739B1 (en) 2006-02-15
ATE420649T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
Murphy Antiglucocorticoid therapies in major depression: a review
JP6175364B2 (ja) 子宮内膜増殖を抑制するための組成物および方法
JP6532754B2 (ja) エストロゲン関連疾患を治療するまたは予防するための方法
CN100531738C (zh) (11β,17β)-11-(1,3-苯并间二氧杂环戊烯-5-基)-17-羟基-17-(1-丙炔基)雌-4,9-二烯-3-酮在治疗重性抑郁症中的应用
US6696432B1 (en) Combination of dehydroepiandrosterone and aromatase inhibitors and use of this combination to produce a medicament for treating relative and absolute androgen deficiency in men
US8193172B2 (en) Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
AU2002348996A1 (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatement of major depressive disorder
HK1087357B (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
US20030229063A1 (en) Use of 4-hydroxytestosterone to lower estrogen levels in humans
US20090118253A1 (en) Compositions and methods for treating dysfunctional uterine bleeding
TW200950788A (en) Compositions and methods for male contraception

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ORGANON NV

Free format text: FORMER OWNER: AKZO NOVEL N.V. CORP.

Effective date: 20070126

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070126

Address after: Holland

Applicant after: Organon NV

Address before: Holland Arnhem

Applicant before: Akzo Nobel N. V.

C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: POP TEST CORTISOL LLC

Free format text: FORMER OWNER: ORGANON NV

Effective date: 20110419

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: OSS, NETHERLANDS TO: NEW JERSEY, THE USA

TR01 Transfer of patent right

Effective date of registration: 20110419

Address after: new jersey

Patentee after: Pop beta cortisol limited liability company

Address before: Holland

Patentee before: Organon NV

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090826

Termination date: 20141021

EXPY Termination of patent right or utility model